Unnati Pharmax

Epclusa – Velakast Tablet
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
International Trade Name: Epclusa®

Epclusa – Velakast Tablet is a fixed-dose combination antiviral tablet containing Sofosbuvir and Velpatasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection. Manufactured in WHO-GMP certified facilities, Velakast Tablets support comprehensive HCV management across all genotypes.

Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir is an NS5A inhibitor. Together, they work synergistically to block HCV replication and eliminate the virus from the body. Epclusa – Velakast is primarily indicated for the treatment of adults with chronic hepatitis C infection, including patients with compensated cirrhosis or without cirrhosis, across all major HCV genotypes.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Velakast Tablets are suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Twinaqt Tablets
Composition: Dolutegravir 50 mg + Lamivudine 300 mg
International Trade Name: Dovato®

Twinaqt Tablets is a high-quality fixed-dose combination tablet containing Dolutegravir and Lamivudine, a biosimilar of the internationally recognized antiretroviral therapy marketed under the brand name Dovato®. Manufactured in WHO-GMP certified facilities by Emcure Pharmaceuticals, Twinaqt supports advanced HIV treatment programs.

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome, while Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits viral replication. The combination provides potent, once-daily antiretroviral therapy for the treatment of HIV-1 infection in adults and adolescents.

Twinaqt Tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, these tablets are suitable for hospitals, clinics, government HIV programs, and international pharmaceutical distribution.

Hepcinat Tablet
Composition: Sofosbuvir 400 mg
International Trade Name: Sovaldi®

Hepcinat Tablet is a high-quality antiviral tablet containing Sofosbuvir, a direct-acting nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B polymerase. Manufactured in WHO-GMP certified facilities, Hepcinat provides effective therapy for chronic hepatitis C infection.

Sofosbuvir works by inhibiting HCV RNA polymerase, thereby preventing viral replication and promoting viral clearance. Hepcinat is indicated for the treatment of adult patients with chronic hepatitis C infection, including patients with compensated cirrhosis or without cirrhosis, and can be used in combination with other antiviral agents as per treatment guidelines.

The tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Hepcinat is suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Sofokast 400 Capsule
Composition: Sofosbuvir 400mg
International Trade Name: Sovaldi®

Sofokast 400 is a high-quality Sofosbuvir 400mg Capsule, a trusted equivalent of the internationally recognized antiviral agent Sovaldi®. Manufactured in WHO-GMP certified facilities, Sofokast Capsules are supplied by reliable pharmaceutical exporters from India to support advanced hepatitis C treatment programs globally.

Sofosbuvir is a potent direct-acting antiviral (DAA) that inhibits the hepatitis C virus (HCV) RNA polymerase, blocking viral replication. Sofokast 400 is primarily indicated for the treatment of chronic hepatitis C infection in adults, including in combination with other antiviral agents, providing high cure rates across multiple HCV genotypes.

Sofokast 400 Capsule is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, and international pharmaceutical distributors.

Leucorin Tablet
Composition: Calcium Folinate 15 mg
International Trade Name: Leucovorin®

Leucorin Tablet is a high-quality oral tablet containing Calcium Folinate, a reduced form of folic acid used to enhance the efficacy and reduce the toxicity of certain chemotherapeutic agents. Manufactured in WHO-GMP certified facilities, Leucorin supports safe and effective treatment protocols in oncology and metabolic disorders.

Calcium Folinate works by replenishing folate stores in the body and protecting healthy cells from the toxic effects of folic acid antagonists such as methotrexate. Leucorin is primarily indicated as a “rescue” therapy in high-dose methotrexate treatment, in combination chemotherapy regimens, and for the management of folate deficiency or certain anemias.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Leucorin Tablets are suitable for hospitals, oncology centers, and pharmacies.

Sovihep V Tablet
Composition: Velpatasvir 100 mg + Sofosbuvir 400 mg
International Trade Name: Epclusa®

Sovihep V Tablet is a high-quality fixed-dose combination antiviral tablet containing Velpatasvir and Sofosbuvir, designed for the treatment of chronic hepatitis C virus (HCV) infection across all genotypes. Manufactured in WHO-GMP certified facilities, Sovihep V supports effective and broad-spectrum HCV therapy.

Velpatasvir, an NS5A inhibitor, and Sofosbuvir, an NS5B polymerase inhibitor, act synergistically to block viral replication and promote complete viral clearance. Sovihep V is primarily indicated for adult patients with chronic hepatitis C infection, including those with or without compensated cirrhosis, providing a comprehensive treatment option.

The tablets are manufactured under strict GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Sovihep V is suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Sofovir / Daclahep Tablet
Composition: Sofosbuvir 400 mg + Daclatasvir 60 mg
Manufacturer: Hetero Labs
International Trade Name: Darvoni

Sofovir / Daclahep Tablet is a high-quality fixed-dose combination antiviral tablet containing Sofosbuvir and Daclatasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes. Manufactured in WHO-GMP certified facilities, these tablets provide safe and effective therapy for HCV management.

Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Daclatasvir, an NS5A inhibitor, act together to inhibit viral replication and promote complete viral clearance. Sofovir / Daclahep is indicated for adult patients with chronic hepatitis C infection, including those with or without compensated cirrhosis, as part of standard antiviral therapy.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Sofovir / Daclahep tablets are suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

RESOF HepCfix Tablets
Composition: Sofosbuvir + Daclatasvir
International Trade Name: Harvoni® / Darvoni® / Sovodak®

RESOF HepCfix Tablets is a high-quality fixed-dose combination containing Sofosbuvir and Daclatasvir, developed as a biosimilar to internationally recognized Hepatitis C therapies marketed under brand names such as Darvoni® and Sovodak®. Manufactured in WHO-GMP certified facilities by Dr. Reddy’s Laboratories, RESOF HepCfix supports advanced antiviral treatment programs for chronic Hepatitis C virus (HCV) infection.

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, while Daclatasvir is an inhibitor of the HCV NS5A protein. Together, they provide once-daily, potent therapy for the treatment of chronic HCV infection across multiple genotypes, including patients with compensated cirrhosis.

RESOF HepCfix Tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Rebetol / Ribasure 200 mg Capsule
Composition: Ribavirin 200 mg
International Trade Name: Rebetol®

Rebetol / Ribasure 200 mg Capsule is a high-quality oral antiviral capsule containing Ribavirin, a broad-spectrum antiviral agent used in the treatment of chronic hepatitis C virus (HCV) infection. Manufactured in WHO-GMP certified facilities, these capsules provide safe and effective therapy, often in combination with other antiviral agents.

Ribavirin works by inhibiting viral RNA synthesis and replication, thereby reducing the viral load and supporting viral clearance. Rebetol / Ribasure is primarily indicated for adult patients with chronic hepatitis C infection, particularly in combination with interferon or direct-acting antiviral agents, according to clinical treatment guidelines.

The capsules are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Rebetol / Ribasure 200 mg Capsules are suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Hepcinat Natdac Tablets
Composition: Sofosbuvir 400 mg + Daclatasvir 60 mg
International Trade Name: Darvoni® / Sovodak®

Hepcinat Natdac is a high-quality fixed-dose combination tablet of Sofosbuvir 400 mg and Daclatasvir 60 mg, a reliable generic equivalent of the internationally recognized direct-acting antiviral (DAA) agents marketed under the brand names Darvoni® and Sovodak®. Manufactured in WHO-GMP certified facilities, Hepcinat Natdac Tablets are supplied by trusted pharmaceutical exporters from India to support global hepatitis C treatment programs.

Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, and Daclatasvir is an NS5A replication complex inhibitor. Together, they act synergistically to block hepatitis C virus (HCV) replication, offering high cure rates across multiple HCV genotypes. Hepcinat Natdac Tablets are primarily indicated for the treatment of chronic hepatitis C infection in adult and adolescent patients, including those with compensated liver disease, and can be used in both treatment-naïve and treatment-experienced patients.

Hepcinat Natdac Sofosbuvir and Daclatasvir Tablets are manufactured under stringent GMP quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, specialty clinics, government hepatitis programs, and international pharmaceutical distributors.

SOVIHEP-V Tablets
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
International Trade Name: Epclusa®

SOVIHEP-V Tablets is a high-quality fixed-dose combination tablet containing Sofosbuvir and Velpatasvir, a biosimilar of the internationally recognized Hepatitis C therapy marketed under the brand name Epclusa®. Manufactured in WHO-GMP certified facilities, SOVIHEP-V supports advanced antiviral treatment programs worldwide.

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, while Velpatasvir is an inhibitor of the HCV NS5A protein. Together, they provide potent, once-daily, pan-genotypic therapy for chronic Hepatitis C virus (HCV) infection across all genotypes, including patients with compensated cirrhosis.

SOVIHEP-V Tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with full regulatory documentation, suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Ribavac 200 mg Capsule
Composition: Ribavirin 200 mg
International Trade Name: Copegus® / Rebetol®

Ribavac 200 mg Capsule is a high-quality Ribavirin 200 mg oral capsule, a biosimilar equivalent of the internationally recognized antiviral medication marketed under brand names such as Copegus® and Rebetol®. Manufactured in WHO-GMP certified facilities, Ribavac Capsules are designed to support global healthcare programs for the treatment of viral infections, particularly chronic hepatitis C.

Ribavirin is a broad-spectrum antiviral agent that works by inhibiting viral RNA synthesis and replication. Ribavac 200 mg Capsules are primarily indicated for the treatment of chronic hepatitis C infection, often in combination with interferon therapy, and for certain other viral infections as per clinical guidelines.

The capsules are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Ribavac Capsules are suitable for hospitals, clinics, and international pharmaceutical distribution.

Sofokast Plus Capsule
Composition: Daclatasvir 60mg + Sofosbuvir 400mg
International Trade Names: Darvoni®, Sovodak®

Sofokast Plus is a high-quality Daclatasvir 60mg + Sofosbuvir 400mg Capsule, a trusted combination therapy equivalent to internationally recognized antiviral agents Darvoni® and Sovodak®. Manufactured in WHO-GMP certified facilities, Sofokast Plus Capsules are supplied by reliable pharmaceutical exporters from India to support comprehensive hepatitis C treatment programs worldwide.

This combination therapy leverages the complementary mechanisms of action of its components: Sofosbuvir, a potent nucleotide analog inhibitor of the HCV RNA polymerase, and Daclatasvir, an NS5A inhibitor that prevents viral replication and assembly. Sofokast Plus is primarily indicated for the treatment of chronic hepatitis C infection, including in patients with multiple genotypes, offering high cure rates when used alone or in combination with other antiviral agents.

Sofokast Plus Capsule is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, government health programs, and international pharmaceutical distributors.

Xapavir Tablet
Composition: Dolutegravir 50 mg
International Trade Name: Tivicay®

Xapavir Tablet is a high-quality oral antiretroviral tablet containing Dolutegravir, a potent integrase strand transfer inhibitor (INSTI) used in the treatment of HIV-1 infection. Manufactured in WHO-GMP certified facilities, Xapavir provides effective and reliable therapy as part of combination antiretroviral regimens.

Dolutegravir works by inhibiting HIV integrase, an enzyme critical for viral replication, thereby preventing the integration of viral DNA into the host genome and reducing viral load. Xapavir is indicated for adult and pediatric patients infected with HIV-1, both treatment-naïve and treatment-experienced, as part of combination therapy according to clinical guidelines.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Xapavir Tablets are suitable for hospitals, specialty HIV clinics, and international pharmaceutical distribution.

Velpanat Tablet
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
International Trade Name: Epclusa®

Velpanat Tablet is a high-quality fixed-dose combination tablet containing Sofosbuvir and Velpatasvir, a direct-acting antiviral therapy for chronic hepatitis C virus (HCV) infection. Manufactured in WHO-GMP certified facilities, Velpanat supports effective treatment across all major HCV genotypes.

Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A inhibitor, work together to prevent HCV replication and promote viral clearance. Velpanat is primarily indicated for adult patients with chronic hepatitis C, including those with compensated cirrhosis or without cirrhosis, ensuring broad-spectrum antiviral efficacy.

Velpanat Tablets are produced under stringent GMP and pharmaceutical quality standards, guaranteeing consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Velpanat is suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Epclusa (Sofocure) Tablet
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
International Trade Name: Epclusa®

Epclusa (Sofocure) Tablet is a high-quality fixed-dose combination antiviral tablet containing Sofosbuvir and Velpatasvir, formulated for the treatment of chronic hepatitis C virus (HCV) infection across all genotypes. Manufactured in WHO-GMP certified facilities, Sofocure provides a reliable and effective solution for HCV therapy.

Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A inhibitor, work together to block viral replication and promote viral clearance. Epclusa (Sofocure) is indicated for adult patients with chronic hepatitis C infection, including those with compensated cirrhosis or without cirrhosis, providing broad-spectrum antiviral coverage.

The tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Epclusa (Sofocure) is suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Ribalieva 200 mg Capsules
Composition: Ribavirin 200 mg
International Trade Name: Copegus® / Rebetol®

Ribalieva 200 mg Capsules is a high-quality Ribavirin 200 mg oral capsule, a biosimilar of the internationally recognized antiviral therapy marketed under brand names such as Copegus® and Rebetol®. Manufactured in WHO-GMP certified facilities, Ribalieva Capsules are designed to support advanced treatment programs for viral infections, particularly chronic Hepatitis C virus (HCV) infection.

Ribavirin is a broad-spectrum antiviral agent that inhibits viral RNA synthesis and replication. Ribalieva 200 mg Capsules are primarily indicated for the treatment of chronic hepatitis C infection, often in combination with interferon therapy, and for certain other viral infections as per clinical guidelines.

Ribalieva Capsules are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Twinaqt 50/300 mg Tablets
Composition: Dolutegravir 50 mg + Lamivudine 300 mg
International Trade Name: Dovato®

Twinaqt 50/300 mg Tablets is a high-quality fixed-dose combination tablet containing Dolutegravir and Lamivudine, a biosimilar of the internationally recognized antiretroviral therapy marketed under the brand name Dovato®. Manufactured in WHO-GMP certified facilities, Twinaqt Tablets are designed to support global HIV treatment programs.

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents viral DNA from integrating into the host genome, while Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits viral replication. The combination provides potent, once-daily antiretroviral therapy for the treatment of HIV-1 infection in adults and adolescents.

Twinaqt Tablets are manufactured under strict GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, these tablets are suitable for hospitals, clinics, government HIV programs, and international pharmaceutical distribution.

INSTGRA Tablets
Composition: Dolutegravir 50 mg
International Trade Name: Tivicay®

INSTGRA Tablets is a high-quality Dolutegravir 50 mg oral tablet, a biosimilar of the internationally recognized antiretroviral therapy marketed under the brand name Tivicay®. Manufactured in WHO-GMP certified facilities, INSTGRA supports advanced HIV treatment programs for adults and adolescents.

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of HIV DNA into the host genome, preventing viral replication. It is primarily indicated for the treatment of HIV-1 infection, either as part of combination antiretroviral therapy or in fixed-dose combination regimens.

INSTGRA Tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, these tablets are suitable for hospitals, clinics, government HIV programs, and international pharmaceutical distribution.

HEPCVEL Tablets
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
International Trade Name: Epclusa®

HEPCVEL Tablets is a high-quality fixed-dose combination tablet containing Sofosbuvir and Velpatasvir, a biosimilar of the internationally recognized Hepatitis C treatment marketed under the brand name Epclusa®. Manufactured in WHO-GMP certified facilities, HEPCVEL is designed to support global antiviral therapy programs.

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, and Velpatasvir is an inhibitor of the HCV NS5A protein. Together, they provide a potent, once-daily, pan-genotypic therapy for the treatment of chronic Hepatitis C virus (HCV) infection across all major genotypes, with or without compensated cirrhosis.

HEPCVEL Tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with full regulatory documentation, making them suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Resof Total Tablets
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
International Trade Name: Epclusa®

Resof Total Tablets is a high-quality fixed-dose combination containing Sofosbuvir and Velpatasvir, a biosimilar of the internationally recognized Hepatitis C therapy marketed under the brand name Epclusa®. Manufactured in WHO-GMP certified facilities, Resof Total supports advanced antiviral treatment programs for chronic Hepatitis C virus (HCV) infection.

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, and Velpatasvir is an inhibitor of the HCV NS5A protein. Together, they provide once-daily, pan-genotypic therapy effective against all HCV genotypes, including patients with compensated cirrhosis.

Resof Total Tablets are produced under strict GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with full regulatory documentation, making them suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

HEPCINAT PLUS 60 mg / 400 mg Tablets
Composition: Daclatasvir 60 mg + Sofosbuvir 400 mg
International Trade Name: Darvoni® / Sovodak®

HEPCINAT PLUS Tablets is a high-quality fixed-dose combination containing Daclatasvir and Sofosbuvir, a biosimilar of the internationally recognized Hepatitis C therapies marketed under the brand names Darvoni® and Sovodak®. Manufactured in WHO-GMP certified facilities, HEPCINAT PLUS supports advanced antiviral treatment programs for chronic Hepatitis C virus (HCV) infection.

Daclatasvir is an inhibitor of the HCV NS5A protein, while Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase. Together, they provide potent, once-daily therapy for the treatment of chronic HCV infection across multiple genotypes, including patients with compensated cirrhosis.

HEPCINAT PLUS Tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with full regulatory documentation, suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Nitib 140 mg Capsule
Composition: Ibrutinib 140 mg
International Trade Name: Imbruvica®

Nitib 140 mg Capsule is a high-quality oral capsule containing Ibrutinib, a targeted therapy designed for the treatment of certain hematologic malignancies. Manufactured in WHO-GMP certified facilities, Nitib provides a reliable treatment option for patients with B-cell cancers.

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that works by blocking B-cell receptor signaling, which is essential for the growth and survival of malignant B-cells. Nitib is primarily indicated for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and other B-cell malignancies as per approved guidelines.

The capsules are manufactured under strict GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Nitib 140 mg Capsules are suitable for hospitals, specialty oncology clinics, and international pharmaceutical distribution.

OLPAVIR-75 Capsules
Composition: Oseltamivir Phosphate 75 mg
International Trade Name: Tamiflu®

OLPAVIR-75 Capsules is a high-quality Oseltamivir 75 mg oral capsule, a biosimilar of the internationally recognized antiviral therapy marketed under the brand name Tamiflu®. Manufactured in WHO-GMP certified facilities, OLPAVIR-75 is designed to support global influenza prevention and treatment programs.

Oseltamivir is a neuraminidase inhibitor that prevents the release of new influenza virus particles from infected cells, reducing the severity and duration of influenza A and B infections. It is primarily indicated for the treatment and prophylaxis of influenza in adults and children, as per clinical guidelines.

OLPAVIR-75 Capsules are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, and international pharmaceutical distribution.

Amdatime 100 Capsule
Composition: Amantadine Hydrochloride 100mg
International Trade Name: Symmetrel®

Amdatime 100 is a high-quality Amantadine Hydrochloride 100mg Capsule, a trusted equivalent of the internationally recognized agent Symmetrel®. Manufactured in WHO-GMP certified facilities, Amdatime Capsules are supplied by reliable pharmaceutical exporters from India to support neurological and antiviral treatment programs.

Amantadine Hydrochloride works by enhancing dopamine activity in the nervous system and inhibiting viral replication. It is indicated for the management of Parkinson’s disease, drug-induced extrapyramidal reactions, and influenza A viral infections. Amdatime 100 Capsule is suitable for patients requiring symptomatic relief from Parkinsonism or antiviral therapy.

Quality Assurance:
Amdatime 100 Capsule is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsule is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, and international pharmaceutical distributors.

Natdac 60 mg Tablets
Composition: Daclatasvir 60 mg
International Trade Name: Daklinza®

Natdac 60 mg Tablets is a high-quality Daclatasvir 60 mg oral tablet, a biosimilar of the internationally recognized antiviral therapy marketed under the brand name Daklinza®. Manufactured in WHO-GMP certified facilities, Natdac Tablets are designed to support advanced treatment programs for chronic Hepatitis C virus (HCV) infection.

Daclatasvir is a direct-acting antiviral (DAA) that inhibits the HCV NS5A protein, blocking viral replication. Natdac 60 mg Tablets are primarily indicated for use in combination with Sofosbuvir for the treatment of chronic HCV infection across multiple genotypes, including patients with compensated cirrhosis.

Natdac Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Dacihep Tablet
Composition: Daclatasvir 60 mg
International Trade Name: Daklinza®

Dacihep Tablet is a high-quality oral antiviral tablet containing Daclatasvir, an NS5A inhibitor used in the treatment of chronic hepatitis C virus (HCV) infection. Manufactured in WHO-GMP certified facilities, Dacihep provides effective therapy for HCV, often as part of combination antiviral regimens.

Daclatasvir works by inhibiting the NS5A protein of HCV, which is essential for viral replication and assembly, thereby preventing the virus from multiplying. Dacihep 60 mg is indicated for adult patients with chronic hepatitis C infection, including those with or without compensated cirrhosis, in combination with other antiviral agents as per standard treatment guidelines.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Dacihep Tablets are suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Immunocin Alpha 1.6 mg Injection
Composition: Thymosin Alpha-1 1.6 mg
International Trade Name: Zadaxin®

Immunocin Alpha 1.6 mg Injection is a high-quality Thymosin Alpha-1 injection, a biosimilar of the internationally recognized immunomodulatory peptide marketed under the brand name Zadaxin®. Manufactured in WHO-GMP certified facilities, this injection is designed to support advanced healthcare and immunotherapy programs.

Thymosin Alpha-1 is a synthetic peptide that enhances the body’s immune response by promoting T-cell activity and supporting antiviral and anticancer immunity. This injection is primarily indicated for use in patients with viral infections, chronic hepatitis, immunodeficiency conditions, and as an adjuvant in certain cancer therapies.

The injection is manufactured under strict GMP and biologics quality standards, ensuring consistent safety, efficacy, and stability. It is supplied in secure, cold-chain compliant packaging with complete regulatory documentation, making it suitable for hospital infusion centers, tertiary care hospitals, and government healthcare programs.

HEPCINAT 400 mg Tablets
Composition: Sofosbuvir 400 mg
International Trade Name: Sovaldi®

HEPCINAT 400 mg Tablets is a high-quality Sofosbuvir 400 mg oral tablet, a biosimilar of the internationally recognized antiviral therapy marketed under the brand name Sovaldi®. Manufactured in WHO-GMP certified facilities, HEPCINAT Tablets are designed to support global Hepatitis C treatment programs.

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase that prevents viral replication. HEPCINAT 400 mg Tablets are primarily indicated for the treatment of chronic Hepatitis C virus (HCV) infection across multiple genotypes, often used in combination with other antiviral agents as per clinical guidelines.

HEPCINAT Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Hepahealth Tablets
Composition: Proprietary liver support formulation
International Trade Name: Livogen® / Essentiale®

Hepahealth Tablets is a high-quality liver support supplement designed to promote liver health and enhance its natural detoxification processes. Manufactured in WHO-GMP certified facilities, Hepahealth is formulated to support patients with liver function concerns and to maintain overall hepatic well-being.

These tablets help protect liver cells, improve metabolic function, and support recovery from mild liver stress caused by lifestyle factors, medications, or mild hepatic disorders. Hepahealth is suitable for use as a supplement in patients requiring additional liver support, in consultation with healthcare professionals.

Hepahealth Tablets are produced under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, suitable for hospitals, clinics, and healthcare distributors.

Hepa-Health Tablet
Composition: Multicomponent hepatoprotective formulation (e.g., Silymarin, vitamins, antioxidants – formulation may vary by manufacturer)
Indication: Liver support and hepatoprotection

Hepa-Health Tablets are high-quality oral tablets formulated to support liver health and function. Manufactured in WHO-GMP certified facilities, these tablets are designed to help maintain optimal liver function, promote detoxification, and protect liver cells from oxidative stress and damage.

The formulation works by enhancing liver enzyme activity, supporting regeneration of liver cells, and providing antioxidant protection. Hepa-Health Tablets are primarily indicated for individuals with liver disorders, fatty liver, mild hepatic impairment, or those requiring liver support due to lifestyle or medication-related stress.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Hepa-Health Tablets are suitable for hospitals, clinics, and pharmacies.

HEPAREL 100 IU
Composition: Hepatitis B Immunoglobulin IP 100 IU / 1 ml
International Trade Name: Hepatect® / HyperHEP B®

HEPAREL 100 IU is a high-quality Hepatitis B Immunoglobulin injection, a purified human immunoglobulin specifically formulated to provide passive immunity against hepatitis B virus (HBV). Manufactured in WHO-GMP certified facilities, HEPAREL is intended to support global vaccination and post-exposure prophylaxis programs.

Hepatitis B Immunoglobulin provides immediate short-term protection by supplying high-titer antibodies against the hepatitis B surface antigen (HBsAg). It is primarily indicated for post-exposure prophylaxis in individuals exposed to HBV, including newborns of HBsAg-positive mothers, accidental needle-stick injuries, and other high-risk exposures.

HEPAREL 100 IU is produced under stringent GMP and biologics quality standards, ensuring consistent safety, efficacy, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with full regulatory documentation, making it suitable for hospitals, clinics, government immunization programs, and international healthcare distribution.

Guficin Injection
Composition: Thymosin Alpha-1
International Trade Name: Zadaxin®

Guficin Injection is a high-quality Thymosin Alpha-1 preparation, a biosimilar of the internationally recognized immunomodulatory peptide marketed under the brand name Zadaxin®. Manufactured in WHO-GMP certified facilities, Guficin supports advanced immune therapy programs for patients with viral infections, immunodeficiency, and as an adjuvant in certain cancer treatments.

Thymosin Alpha-1 is a synthetic peptide that enhances the body’s immune response by stimulating T-cell activity and modulating cytokine production. It is primarily indicated for immune support in viral infections, chronic hepatitis, immunodeficiency conditions, and as an adjunct in oncology and immunotherapy protocols.

Guficin Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent safety, efficacy, and stability. The injection is supplied in secure, cold-chain compliant packaging with complete regulatory documentation, suitable for hospitals, clinics, and international healthcare distribution.

Hepcinat Plus Tablets
Composition: Sofosbuvir 400 mg + Daclatasvir 60 mg
International Trade Name: Darvoni® / Sovodak®

Hepcinat Plus Tablets is a high-quality fixed-dose combination containing Sofosbuvir and Daclatasvir, a biosimilar of the internationally recognized Hepatitis C therapies marketed under the brand names Darvoni® and Sovodak®. Manufactured in WHO-GMP certified facilities, Hepcinat Plus supports advanced antiviral treatment programs for chronic Hepatitis C virus (HCV) infection.

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, while Daclatasvir is an inhibitor of the HCV NS5A protein. Together, they provide once-daily, potent therapy for the treatment of chronic HCV infection across multiple genotypes, including patients with compensated cirrhosis.

Hepcinat Plus Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. The tablets are supplied in secure, export-grade packaging with full regulatory documentation, suitable for hospitals, clinics, government hepatitis programs, and international pharmaceutical distribution.

Velasof Tablet
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
International Trade Name: Epclusa®

Velasof Tablet is a high-quality fixed-dose combination antiviral tablet containing Sofosbuvir and Velpatasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes. Manufactured in WHO-GMP certified facilities, Velasof provides a reliable and effective therapeutic option for HCV management.

Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A inhibitor, work synergistically to block viral replication and promote complete viral clearance. Velasof is indicated for adult patients with chronic hepatitis C infection, including those with compensated cirrhosis or without cirrhosis.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Velasof is suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Zidolam Tablet
Composition: Zidovudine 300 mg
International Trade Name: Retrovir®

Zidolam Tablet is a high-quality oral antiretroviral tablet containing Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV-1 infection. Manufactured in WHO-GMP certified facilities, Zidolam provides safe and effective therapy as part of combination antiretroviral regimens.

Zidovudine works by inhibiting HIV reverse transcriptase, an enzyme essential for viral replication, thereby reducing viral load and helping to maintain immune function. Zidolam is indicated for adult and pediatric patients with HIV-1 infection, both treatment-naïve and treatment-experienced, as part of combination therapy according to clinical guidelines.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Zidolam Tablets are suitable for hospitals, specialty HIV clinics, and international pharmaceutical distribution.

RESOF / HepCfix Tablet
Composition: Sofosbuvir 400 mg + Daclatasvir 60 mg
Manufacturer: Dr. Reddy’s Laboratories
International Trade Name: Darvoni

RESOF / HepCfix Tablet is a high-quality fixed-dose combination antiviral tablet containing Sofosbuvir and Daclatasvir, formulated for the treatment of chronic hepatitis C virus (HCV) infection across multiple genotypes. Manufactured in WHO-GMP certified facilities, these tablets provide effective, reliable, and broad-spectrum antiviral therapy.

Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Daclatasvir, an NS5A inhibitor, act synergistically to block HCV replication and achieve complete viral clearance. RESOF / HepCfix is indicated for adult patients with chronic hepatitis C infection, including those with or without compensated cirrhosis, as part of standard antiviral therapy.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, RESOF / HepCfix tablets are suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Qurled-V Tablet
Composition: Sofosbuvir 400 mg + Velpatasvir 100 mg
Manufacturer: Strides Shasun
International Trade Name: Epclusa®

Qurled-V Tablet is a high-quality fixed-dose combination antiviral tablet containing Sofosbuvir and Velpatasvir, formulated for the treatment of chronic hepatitis C virus (HCV) infection across all genotypes. Manufactured in WHO-GMP certified facilities, Qurled-V provides an effective and broad-spectrum therapy for HCV management.

Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A inhibitor, act synergistically to block viral replication and achieve viral clearance. Qurled-V is indicated for adult patients with chronic hepatitis C infection, including those with or without compensated cirrhosis.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Qurled-V is suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Sofokast / Dacikast / Aprazer Tablet
Composition: Sofosbuvir 400 mg + Daclatasvir 60 mg
International Trade Name: Darvoni® / Sovodak®

Sofokast / Dacikast / Aprazer Tablet is a high-quality fixed-dose combination antiviral tablet containing Sofosbuvir and Daclatasvir, formulated for the treatment of chronic hepatitis C virus (HCV) infection. Manufactured in WHO-GMP certified facilities, these tablets provide effective therapy across multiple HCV genotypes.

Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Daclatasvir, an NS5A inhibitor, act synergistically to block viral replication and support complete viral clearance. These tablets are indicated for adult patients with chronic hepatitis C infection, including those with compensated cirrhosis or without cirrhosis, as part of standard antiviral therapy.

The tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent safety, efficacy, and stability. Supplied in secure, export-grade packaging with complete regulatory documentation, Sofokast / Dacikast / Aprazer tablets are suitable for hospitals, specialty clinics, and international pharmaceutical distribution.

Sovihep / Dacihep Tablets
Composition: Sofosbuvir 400 mg + Daclatasvir 60 mg Tablets IP
International Trade Names: Sovihep®, Dacihep®, Zydus®, Heptiza®, Darvoni®, Sovodak®

Sovihep / Dacihep is a high-quality fixed-dose combination tablet containing Sofosbuvir 400 mg and Daclatasvir 60 mg, a reliable generic equivalent of internationally recognized antiviral therapies marketed under various brand names. Manufactured in WHO-GMP certified facilities, these tablets are supplied by trusted pharmaceutical exporters from India to support global hepatitis C management programs.

Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, and Daclatasvir is a potent NS5A replication complex inhibitor. Together, they act synergistically to inhibit hepatitis C virus (HCV) replication, leading to sustained virologic response and effective viral clearance. Sovihep / Dacihep Tablets are primarily indicated for the treatment of chronic hepatitis C infection (all genotypes), including patients with compensated liver disease, with or without co-infection, in both treatment-naïve and treatment-experienced individuals.

Sovihep / Dacihep Sofosbuvir and Daclatasvir Tablets are manufactured under stringent GMP quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, specialized liver treatment centers, government healthcare programs, and international pharmaceutical distributors.